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ARTICLE
Zwitterionically modiﬁed alginates mitigate cellular
overgrowth for cell encapsulation
Qingsheng Liu1, Alan Chiu1, Long-Hai Wang1, Duo An 1, Monica Zhong1, Alexandra M. Smink2,
Bart J. de Haan2, Paul de Vos2, Kevin Keane 3, Andreas Vegge4, Esther Y. Chen5, Wei Song1, Wendy F. Liu5,
James Flanders6, Claude Rescan7, Lars Groth Grunnet7, Xi Wang1 & Minglin Ma 1*
Foreign body reaction (FBR) to implanted biomaterials and medical devices is common and
can compromise the function of implants or cause complications. For example, in cell
encapsulation, cellular overgrowth (CO) and ﬁbrosis around the cellular constructs can
reduce the mass transfer of oxygen, nutrients and metabolic wastes, undermining cell
function and leading to transplant failure. Therefore, materials that mitigate FBR or CO will
have broad applications in biomedicine. Here we report a group of zwitterionic, sulfobetaine
(SB) and carboxybetaine (CB) modiﬁcations of alginates that reproducibly mitigate the CO of
implanted alginate microcapsules in mice, dogs and pigs. Using the modiﬁed alginates (SB-
alginates), we also demonstrate improved outcome of islet encapsulation in a chemically-
induced diabetic mouse model. These zwitterion-modiﬁed alginates may contribute to the
development of cell encapsulation therapies for type 1 diabetes and other hormone-deﬁcient
diseases.
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Type 1 diabetes (T1D) affects millions of people worldwide,despite that many advanced therapeutic treatments havebeen developed1–8. To date, daily injection or infusion of
exogenous insulin is still the leading treatment option to provide
blood glucose (BG) control for people with T1D9. However,
insulin therapies are tedious, often associated with patient com-
pliance and cannot totally prevent diabetic side effects10. Pan-
creatic islet transplantation has worked for some patients11, but it
is limited to only a small fraction of patients because of a shortage
of donor islets and the need for long-term immuno-suppression.
Recently, human stem cell-derived beta (SC-β) cells have been
developed, providing a pathway to produce an unlimited supply
of insulin-producing cells12,13. However, these cells still need to
be immunoprotected or encapsulated to prevent the immune and
autoimmune responses.
Cell encapsulation has indeed shown great promise in
numerous animal studies. Among the different materials used for
cell encapsulation, alginate is one of the most prevalent ones to
date14–16, due in a large part to its mild gelation conditions and
minimal toxicity15–18. However, foreign body reaction (FBR), a
complex process involving protein adsorption, monocyte/granu-
locytes/macrophage adhesion, giant cell formation, and cross-
talks between macrophages/giant cells and other immune/ﬁbro-
blast cells, against alginate microcapsules is often observed and
can be further elevated by encapsulated cells or xenogeneic donor
tissue5,19,20. The cellular overgrowth (CO) and the ﬁbrosis, an
end result of the FBR21,22 that the body forms to isolate foreign
implants reduce and even cut off the diffusion of nutrients and
oxygen to the encapsulated cells, causing cell necrosis. To mitigate
the CO of alginate microcapsules, investigators recently took an
expensive, time-consuming but effective high throughput
approach. Vegas et al. created a library of almost 800 chemically
modiﬁed alginate derivatives and identiﬁed a few “hits” (e.g., Z1-
Y15 containing triazole group) that effectively mitigated CO in
mice and non-human primates23,24.
We report here a totally different, more rational and much less
expensive approach to develop CO-mitigating, chemically mod-
iﬁed alginates. Nonspeciﬁc protein adsorption onto implanted
material is considered the ﬁrst and critical step of FBR25–27. An
antifouling material or surface that is highly resistant to protein
adsorption and cell attachment is expected to suppress FBR and
subsequently the CO and formation of ﬁbrosis25. Recently,
zwitterionic polymers, bearing zwitterions of carboxybetaine
(CB), sulfobetaine (SB) and phosphorycholine, have been exten-
sively studied in regards to their ultra-low-fouling properties28–30.
For example, zwitterionic poly(carboxybetaine methacrylate)
(PCBMA) hydrogels have been shown to resist the formation of
ﬁbrotic capsule for at least 3 months after subcutaneous
implantation in mice26. Based on these previous studies, we
rationalized that chemically modifying alginate with zwitterionic
groups might lead to a different class of CO-mitigating alginate
derivatives.
We ﬁrst modify alginates (Ultrapure VLVG, SLG20, SLG100)
with a zwitterionic group, SB and ﬁnd that the modiﬁcation
reproducibly reduces the CO of the alginate microcapsules (dia-
meter: 500~700 µm) in different species: C57BL/6J mice (intra-
peritoneal implantation), dogs (intraperitoneal) and pigs
(omental pouch). To show the observed effect is reproducible, we
have done a total of 17 mouse experiments with different types of
alginates and different time points up to 6 months. Consistently,
the SB-alginate microcapsules induce signiﬁcantly less CO than
the unmodiﬁed control and most of the times almost free of CO.
Interestingly, the CO-mitigating effect of the zwitterionic mod-
iﬁcation is also observed in carboxybetaine-based alginates (i.e.,
CB-alginates). Additional experiments in large animals including
dogs and pigs show similarly reduced CO of the SB-alginate
compared to the unmodiﬁed SLG20 or SLG100, indicating the
potential translatability of the zwitterionic modiﬁcation. Then we
encapsulate rat islets using either the SB-alginate microcapsules
or unmodiﬁed control microcapsules and transplant them
intraperitoneally in C57BL/6J mice with streptozotocin (STZ)-
induced diabetes. The SB-alginate microcapsules result in sig-
niﬁcantly better long-term glycemic control, up to 200 days.
Characterization of retrieved microcapsules and islets conﬁrms
the CO-mitigating property of the SB-alginate microcapsules as
well as islet survival and function. Compared with the previously
published high throughput approach, the zwitterionic modiﬁca-
tion represents a much simpler and less expensive strategy for the
design and development of super-biocompatible alginates. We
believe that these zwitterionically modiﬁed-alginates and our
approach may contribute to a cell encapsulation therapy for T1D
and potentially other hormone-deﬁcient diseases in the future.
Results
Development of zwitterionically modiﬁed alginates. Recently,
zwitterionic polymers and hydrogels have been extensively
investigated due to their attractive ultra-low biofouling and bio-
compatible characteristics28. However, harsh required conditions
such as UV irradiation or generation of free radical groups during
the gelation of zwitterionic materials can be harmful to encap-
sulated cells, limiting broad biomedical applications31–33. We
hypothesized that we could overcome this limitation but maintain
the biocompatibility of zwitterionic compounds by developing a
group of zwitterionically modiﬁed alginates. In these alginate
derivatives, the zwitterionic moiety provides high surface hydra-
tion34, resistance to protein adsorption or cell adhesion, and
mitigation of CO, while the alginate backbone remains cross-
linkable with mild gelation condition and allows formation of
microcapsules using an electrospraying technique (Fig. 1a).
Among zwitterionic groups, the SB group was ﬁrstly chosen in
our studies because of its excellent antifouling performance,
commercial availability and low cost35,36. In order to modify the
alginate with SB group, we designed and synthesized SB-NH2
monomer according to Supplementary Fig. 1. Then, we chose low
molecular weight (MW), ultrapure alginate VLVG as the starting
material. 2-chloro-4, 6-dimethoxy-1, 3, 5-triazine (CDMT) and
N-methylmorpholine (NMM) were used as coupling reagents to
conjugate alginate with SB-NH2 via a triazine-based coupling
reaction (Fig. 1b). The SB-based alginate conjugate was
characterized by 1H NMR spectrum (Fig. 1b) where a peak at
3.20 ppm was attributed to the six protons in two methyl groups
attached to the quaternary amine in the SB pendant group. The
result suggested that SB-NH2 was successfully conjugated to
alginate. About 30.5% modiﬁcation degree of the starting alginate
was conﬁrmed by NMR data analysis. Using similar procedures,
we also modiﬁed higher molecular weight alginates, SLG20 and
SLG100.
To examine how the zwitterionic modiﬁcations may have
affected the physiochemical properties of the alginates and
microcapsules, we performed a number of characterizations. First,
the surface roughness of SB-SLG20 and SLG20 microcapsules,
assessed by atomic force microscope (AFM), were 11 ± 1 nm and
17 ± 15 nm, respectively (Supplementary Fig. 2). The SB-SLG20
capsules appeared slightly smoother but these two kinds of alginate
capsules had no statistical difference in the surface roughness. We
then evaluated whether this zwitterion modiﬁcation changed the
surface charge. Zeta-potentials of SLG20 and SB-SLG20 hydrogels
were −17.3 ± 0.5 and −12.2 ± 0.3mV, respectively (Supplementary
Fig. 3). Zeta-potentials of SB-SLG20 and SLG20 hydrogels were
similar and they are both negatively charged polymers. To compare
the mass transfer of the unmodiﬁed and modiﬁed alginate
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13238-7
2 NATURE COMMUNICATIONS |         (2019) 10:5262 | https://doi.org/10.1038/s41467-019-13238-7 | www.nature.com/naturecommunications
hydrogels, we immersed SLG20 and SB-SLG20 hydrogels into
different molecular weight, FITC-labeled dextran standards,
respectively. The results (Supplementary Fig. 4) indicate that the
diffusion rate of SB-SLG20 hydrogel was similar to that of SLG20
hydrogel regardless of molecular weight of dextrans. Since the
mechanical property of the microcapsules is an important
consideration in the success of cell encapsulation, it was evaluated
in our studies by a Texture Analyzer. SB-SLG20 microcapsules
under force were slightly stronger than SLG20 microcapsules
(Supplementary Fig. 5). This might be attributed to the 40%
SLG100 alginate (which has a larger molecular weight than SLG20)
addition during preparation of the SB-SLG20 solution. Taken
together, the zwitterionic modiﬁcation did not seem to change the
physiochemical properties of the microcapsules signiﬁcantly.
Protein adsorption on the surface of an implanted medical
device is the ﬁrst step in a foreign body response, which will
eventually affect the performances of the device25,37. Therefore,
protein adsorption on the modiﬁed alginate was studied in our
work, with unmodiﬁed SLG20 alginate as control. Two model
proteins, ﬁbrinogen (340 kDa, isoelectronic point: 5.5) and
lysozyme (14 kDa, isoelectronic point: 11.1), were used to study
the adsorption on the alginate hydrogel surfaces. These model
proteins represent different molecular weights, structural stability,
and isoelectronic points. Relative to SLG20 hydrogels, the amount
of ﬁbrinogen and lysozyme adsorptions on SB-SLG20 is 20.3 and
9.8%, respectively (Fig. 1c and Supplementary Fig. 6), indicating a
strong resistance to non-speciﬁc protein adsorption. The excellent
antifouling property of SB-SLG20 is probably due to the strong
hydration of the SB groups34.
We then studied macrophage activation on the modiﬁed
alginate hydrogels by seeding murine bone marrow derived
macrophages (BMDM) and examining release of tumor necrosis
factor-α (TNF-α) as a representative pro-inﬂammatory cyto-
kine. After stimulation with lipopolysaccharide/interferon
gamma (LPS/IFNγ) which is known to induce a pro-
inﬂammatory macrophage phenotype38, the BMDMs cultured
on the SB-SLG20 hydrogels secreted lower levels of TNF-α
when compared to those cultured on the SLG20 hydrogels or
tissue culture polystyrene plates (TCPS) (Fig. 1d). This study
demonstrated that incorporating a zwitterionic moiety into
alginate effectively inhibited the inﬂammatory activation of
macrophages in vitro.
We also studied the impact of the alginate microcapsules on toll-
like receptors (TLRs) signaling. TLRs are a class of proteins that
play a key role in the innate immune system39. We used human
embryonic kidney (HEK) cell line that expresses speciﬁc TLR
signaling. The SLG20 and SB-SLG20 microcapsules (Supplementary
Fig. 7) did not activate TLR2 or TLR4 but they did inhibit the
signaling, indicating SLG20 and SB-SLG20 hydrogels were not
immunostimulatory. More interestingly, SB-SLG20 capsules were
shown to inhibit TLR2, more than SLG20 capsules and the control.
These results again point to the potential anti-inﬂammatory effect
of the zwitterionic modiﬁcation.
To explore whether the in vitro anti-fouling and anti-
inﬂammatory properties translate into CO mitigation in vivo,
we performed a number of animal experiments. In addition to the
SB-alginate, we also designed, synthesized and tested two other




















































































































































































Fig. 1 Design of zwitterionically modiﬁed alginates and their in vitro characterizations. a Schematic illustration of zwitterionically modiﬁed alginate
microcapsules encapsulating islets. b Synthetic pathway and 1H NMR characterization of sulfobetaine (SB)-modiﬁcation of alginate. c Adsorption of FITC-
labeled ﬁbrinogen and lysozyme on the surfaces of different alginate hydrogels quantiﬁed by ImageJ. Mean ± SEM; n= 6; *P < 0.05. d Quantiﬁcation of
TNF-α secretion from macrophages cultured on different surfaces. Mean ± SEM; n= 5; *P < 0.05. e Chemical structures of CB1-alginate and CB2-alginate
conjugates
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CB2-alginate, Fig. 1e; see Supplementary Figs. 8 and 9 for related
NH2 terminated monomers CB1-NH2 and CB2-NH2).
Zwitterionically modiﬁed alginates mitigate CO in mice. To
evaluate the biocompatibility of SB-modiﬁed alginates, we ﬁrst
chose immunocompetent C57BL/6J mice because this strain was
previously shown to elicit a strong CO against unmodiﬁed algi-
nate microcapsules40. Microcapsules of SB-VLVG alginate were
fabricated using electrospraying technique and had a uniform
spherical morphology and diameters ranging from 450 to 550 μm,
as shown in Fig. 1a and Supplementary Fig. 10. Unmodiﬁed
SLG20 alginate was processed into microcapsules with similar
size and morphology and used as control. The microcapsules
were implanted in the intraperitoneal space of C57BL/6J mice and
retrieved for characterization 14 days post implantation.
To characterize the CO, we fused dark-ﬁeld microscopic
images of all retrieved microcapsules to obtain a composite view.
In the images, the whiteness on the microcapsule surfaces
(Fig. 2a) indicated the cellular deposition. Clearly, the control
microcapsule (SLG20) as shown in Fig. 2a induced variable and
substantial cellular deposition (see Supplementary Fig. 11 for all
other 18 samples from 6 batches with a total n= 19), which was
consistent with that of previously reported work41. In contrast,
there was almost no cellular deposition observed on the SB-
VLVG alginate microcapsules (Fig. 2a and see Supplementary
Fig. 12 for all other 9 samples from three batches with a total n=
10). The representative H&E staining of microcapsule cross-
sections (Fig. 2a) further conﬁrmed that the surfaces of SB-VLVG
alginate microcapsules were almost free of CO while the surfaces
of SLG20 microcapsules had visible CO. To examine whether
the observation was reproducible, another batch of SB-VLVG
alginate was synthesized and evaluated for CO. This batch of
retrieved SB-VLVG alginate as shown in Supplementary Fig. 12
also exhibited almost no cellular deposition. These results suggest
that SB-VLVG alginate microcapsules mitigated CO effectively
and reproducibly. This may be attributed to the zwitterionic SB
group that increases surface hydration, reduces biofouling and
improves biocompatibility of alginate. We have also compared
directly one of the “hits” from the library screening23 with
SB-VLVG alginates. As shown in Supplementary Fig. 13, there
were minimal and similar levels of cellular depositions on our
modiﬁed alginate and the one based on previous library screening
method23, suggesting comparable biocompatibility despite differ-
ent chemistries and approaches.
SLG20 SB-VLVG SB-SLG20 SB-SLG100 CB1-SLG20 CB2-SLG20
SLG20 SB-VLVG SB-SLG20 SB-SLG100 CB1-SLG20 CB2-SLG20
SLG20 SB-SLG20  CB1-SLG20 CB2-SLG20 SLG20 SB-SLG20
SLG20 SB-SLG20  CB1-SLG20 CB2-SLG20 SLG20 SB-SLG20
a
b c
Fig. 2 SB and CB modiﬁed alginates mitigate CO in mice. a Representative phase-contrast images of retrieved microcapsules made from different alginates
(SLG20, n= 19, see Supplementary Fig. 11 for complete data; SB-VLVG, n= 10, see Supplementary Fig. 12 for complete data; SB-SLG20, n= 16, see
Supplementary Fig. 14 for complete data; SB-SLG100, n= 10, see Supplementary Fig. 15 for complete data; CB1-SLG20, n= 5, see Supplementary Fig. 16a
for complete data; CB2-SLG20, n= 5, see Supplementary Fig. 16b for complete data), 14 d post intraperitoneal implantation in C57BL/6J mice (Scale bar,
2000 μm) and corresponding H&E stained histological analysis (Scale bar, 200 μm). b Representative phase-contrast images of retrieved microcapsules,
100 d post intraperitoneal implantation in C57BL/6J mice (Scale bar, 2000 μm) and corresponding H&E stained histological analysis (Scale bar, 200 μm).
(SLG20, n= 12, see Supplementary Fig. 17 for complete data; SB-SLG20, n= 10, see Supplementary Fig. 18 for complete data; CB1-SLG20, n= 4, see
Supplementary Fig. Supplementary Fig. 20a for complete data; CB2-SLG20, n= 4, see Supplementary Fig. 20b for complete data). c Representative phase-
contrast images of retrieved microcapsules, 180 d post intraperitoneal implantation in C57BL/6J mice (Scale bar, 2000 μm) and corresponding H&E
stained histological analysis (Scale bar, 200 μm). (SLG20, n= 7, see Supplementary Fig. 22 for complete data; SB-SLG20, n= 7, Supplementary Fig. 21 for
complete data)
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To verify that the CO-mitigating effect of SB modiﬁcation does
not depend on the type of alginate, we also synthesized SB-SLG20
alginate and SB-SLG100 alginate using the same method. Due to
their higher molecular weights, the SLG20 (MW: 75–150 kDa)
and SLG100 (MW: 150–250 kDa) form stronger hydrogels than
VLVG alginate (MW< 75 kDa), and may have broader applica-
tions in biomedicine. The SB-SLG20 and SB-SLG100 alginate
microcapsules were implanted in the intraperitoneal space of
C57BL/6J mice and then retrieved after 14 days, with SLG20
microcapsules as control. Dark-ﬁeld images of all retrieved SB-
SLG20 alginate microcapsules (n= 16; Fig. 2a and all other
samples from three batches in Supplementary Fig. 14) and SB-
SLG100 microcapsules (n= 10; Fig. 2a and all other samples from
two batches in Supplementary Fig. 15) showed very little CO.
H&E staining (Fig. 2a) also indicated that there was almost no
CO around retrieved SB-SLG20 and SB-SLG100 alginate micro-
capsules. In contrast, the conventional, unmodiﬁed SLG20
microcapsules induced varied degrees of CO, and some elicited
severe CO. To explore whether other zwitterionic moieties play a
similarly important role in mitigating CO, the biocompatibility of
CB-alginates was evaluated. Interestingly, CB1-SLG20 and CB2-
SLG20 (Fig. 2a and see Supplementary Fig. 16 for all other
samples; n= 5 from one batch) microcapsules were also found to
have little or no CO. Taken together, these results suggest that the
CO-mitigation of zwitterionic modiﬁcation is reproducible, and
independent of alginate or zwitterion types, at least during 2-week
intraperitoneal implantation in mice.
To investigate whether the modiﬁcation can mitigate CO for a
much longer term, we implanted SB-SLG 20 and CB-SLG20
microcapsules in C57BL/6J mice and retrieved them after
100 days. Retrieved SLG20 microcapsules (Fig. 2b and Supple-
mentary Fig. 17, n= 12 from three batches) exhibited signiﬁcant
cellular deposition, which was further veriﬁed by histological
analysis (Fig. 2b). Moreover, some of the retrieved SLG20
microcapsules even aggregated together, a sign of severe FBR
(Supplementary Fig. 17). However, SB-SLG20 microcapsules
(Fig. 2b and Supplementary Fig. 18, n= 10 from two batches)
had a much lower level of cellular deposition, consistent with
histology results (Fig. 2b). We also veriﬁed that SB-SLG100
microcapsules mitigated the CO effectively at 100 days (Supple-
mentary Fig. 19, n= 4) indicating that this CO-mitigating
zwitterionic modiﬁcation is independent of alginate types for
long-term implantation. Moreover, CB1-SLG20 and CB2-SLG20
microcapsules (Fig. 2b and Supplementary Fig. 20, n= 4) also
had almost no CO. To further evaluate the longevity of the CO-
resistant property, SB-SLG20 microcapsules were examined
180 days after implantation in C57BL/6J mice. As shown in
Fig. 2c and Supplementary Fig. 21 (n= 7), SB-SLG20 micro-
capsules were largely free of cellular deposition after retrieval,
which was consistent with H&E staining. However, there was
severe CO observed on the surfaces of unmodiﬁed SLG20
microcapsules (Fig. 2c and Supplementary Fig. 22, n= 7). A
striking difference between the modiﬁed and unmodiﬁed
microcapsules was also observed in macroscopic photos of the
retrieved samples (Supplementary Fig. 21b and 22b). The
retrieved SLG20 microcapsules appeared mostly white in Petri
dishes, indicating severe cellular deposition (Supplementary
Fig. 22b, bottom two rows), while the near transparent
appearance of the retrieved SB-SLG20 microcapsules suggested
negligible CO (Supplementary Fig. 21b, bottom two rows).
To quantify the observations described above, we calculated
retrieval rates (Supplementary Table 1) and categorized all
retrieved microcapsules based on the percentage of surface
coverage by “pericapsular cellular overgrowth” or PCO24,42,43:
0–25, 25–50, 50–75, and 75–100%. For SLG20 control micro-
capsules after 14 days implantation (Fig. 3a), the 0–25% PCO
category (a sign of no or little CO) accounted for 24.5% of all
retrieved microcapsules, and the 75–100% PCO category (a sign
of severe CO) made up to 42.5%. In contrast, more than 90% of
all retrieved zwitterionically modiﬁed microcapsules fell into the
0–25% PCO category, a signiﬁcant improvement over conven-
tional SLG20 microcapsules. Similarly, during long-term
(100–180 days) studies (Figs. 3b, c), 90% of modiﬁed alginate
microcapsules developed minimal CO (i.e. within the 0–25%
PCO category), while almost half of SLG20 control microcapsules
had severe CO (i.e., within the 75–100% PCO category). These
quantiﬁcations suggest that zwitterionic SB and CB modiﬁcations
substantially reduced CO of alginate microcapsules in the
intraperitoneal space of C57BL/6J mice in both short (14 d)
and long terms (100 d). More remarkably, zwitterionic SB-SLG20
was shown to mitigate the CO effectively, up to half a year.
Lastly, to better understand the phenotypes of adhered cells on
the retrieved microcapsules and the innate immune response
caused by zwitterion-modiﬁed and unmodiﬁed alginates, we
implanted SLG20 and SB-SLG20 microcapsules in C57BL/6 mice
for 2 weeks and immunologically analyzed the capsules and the
intraperitoneal ﬂuid surrounding the capsules. The retrieved
capsules were stained by a number of cellular markers including
α-smooth muscle actin (SMA), CD68, F4/80, CD11b, and Ly-6G/


























































































































100 days post-implantation 180 days post-implantation
b c
Fig. 3 PCO evaluation of retrieved microcapsules. a Quantiﬁcation of PCO for retrieved microcapsules, 14 d post implantation. Mean ± SEM; n= 19 for
SLG20; n= 10 for SB-VLVG; n= 16 for SB-SLG20; n= 10 for SB-SLG100; n= 5 for CB1-SLG20; n= 5 for CB2-SLG20. *P < 0.05. b Quantiﬁcation of PCO for
retrieved microcapsules, 100 d post implantation. Mean ± SEM; n= 12 for SLG20; n= 10 for SB-SLG20; n= 4 for CB1-SLG20; n= 4 for CB2-SLG20. *P <
0.05. c Quantiﬁcation of PCO for retrieved microcapsules, 180 d post implantation. Mean ± SEM; n= 7 for SLG20; n= 7 for SB-SLG20. *P < 0.05
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revealed that the cells attached to microcapsules included
monocytes, granulocytes, macrophages and ﬁbroblasts, and there
was a signiﬁcant reduction of adhesion of these cells, particularly
monocytes and neutrophils, after the zwitterionic modiﬁcation
consistent with the phase-contract images.
From immune proﬁling of the peritoneal ﬂuid 2 weeks post
implantation with 40 different cytokines (Supplementary Fig. 27),
we observed interestingly that samples fabricated with modiﬁed
alginate contained less inﬂammatory cytokines/components/che-
mokines in the intraperitoneal ﬂuid than those with unmodiﬁed
control, including C5/C5a, IP-10, TREM-1, IL-1β, IL-1a, CCL1,
CCL2, CCL344,45. TIMP-1 was also downregulated in the samples
made with modiﬁed alginate, which inhibits matrix metallopro-
teinase and promotes ﬁbrosis46. Another interesting observation
was that the unmodiﬁed alginate samples contained CXCL1,
CXCL2, CXCL12, which are powerful neutrophil chemoattractants
that are involved in many immune responses including wound
healing, cancer metastasis, and angiogenesis47. The results from
immunostaining also veriﬁed the neutrophil trafﬁcking in
unmodiﬁed samples (Supplementary Fig. 26). Both modiﬁed and
unmodiﬁed samples contained similar levels of chemokine
CXCL13, which attracts B cells in peritoneum and promotes
antibody production48. M-CSF (CSF1), secreted by macrophages
and ﬁbroblasts, is similarly expressed in both samples and
important for the survival and proliferation of macrophages,
conﬁrming the local milieu of ﬁbroblasts and macrophages49. IL-
16, also expressed by both samples, is a lymphocyte chemoat-
tractant factor for CD4+ lymphocytes, which not only regulates
migration of all CD4+ T cells but also facilitates the expansion of
CD4+ CD25+ Treg cells50. In summary, the immune proﬁling
results seem to suggest that the zwitterionic modiﬁcation
inﬂuenced the cytokine expression in the intraperitoneal ﬂuids
surrounding the capsules and downregulated several inﬂammatory
cytokines particularly neutrophil chemoattractants. More work will
be needed in the future to fully understand the exact roles of all the
cytokines we proﬁled in the host responses against the
microcapsules.
FBR mitigation in dogs and pigs. Next, we explored whether the
observations in mice would translate to large animals such as
dogs and pigs. First, SB-SLG20 microcapsules (~500 µm) were
implanted intraperitoneally into Beagle dogs (n= 3) using a
minimally invasive laparoscopic procedure. Efforts were made to
spread out the microcapsules as much as possible. Unmodiﬁed
SLG20 microcapsules were also implanted in one dog as control.
The biocompatibility of the microcapsules was assessed 45 days
after implantation using a similar laparoscopic procedure. There
was no visible adhesion of SB-SLG20 microcapsules to host tissue
(Fig. 4a), and they were easily dissociated from the implant site
using either saline washing or catheter manipulation. A fraction
of the microcapsules were aspirated out for characterization
(Supplementary Movie 1). In contrast, the SLG20 microcapsules
mostly adhered to the surrounding tissues and some were even
fully embedded (Fig. 4b), making retrieval difﬁcult. Multiple
aspirations were needed to retrieve a sufﬁcient number of
microcapsules for characterization (Supplementary Movie 2).
Dark-ﬁeld microscopic images of retrieved SB-SLG20 micro-
capsules (Fig. 4c and Supplementary Fig. 28) revealed negligible
cellular deposition, which was evidenced by the near transparent
macroscopic appearance (Fig. 4d and Supplementary Fig. 28b).
H&E stained section of retrieved capsules conﬁrmed that there
was minimal cellular deposition on the surfaces (Fig. 4e). In the
contrast, the retrieved SLG20 microcapsules showed presence of
strong CO (Fig. 4f) and many of them were covered with multiple
cell layers (Fig. 4g). Moreover, we assessed the SB-SLG20
microcapsules again at 90 days post implantation from 2 of the
3 dogs that received implants. Still, the microcapsules had almost
no tissue adhesion (Fig. 4h) and were mostly free of cellular
deposition (Fig. 4i, j, and Supplementary Fig. 29).
To further evaluate the FBR to SB-alginate microcapsules, we
chose insulin treated type 1 streptozotocin (STZ)-induced
Göttingen minipigs and implanted SB-SLG100 microcapsules
(Size: 500 ~ 700 μm) into pig omental bursa (n= 2), which is
known to be extremely prone to elicit FBR following surgical
intervention (Supplementary Fig. 30). In contrast to the
laparoscopic implantation in dogs, the microcapsules were
implanted as a whole without being spread out inside the
omentum opening. (See Supplementary Fig. 30 for surgical
details.) Unmodiﬁed SLG100 microcapsules were implanted as
control (n= 2). One month after implantation, we excised the
omentum and histologically analysed the microcapsules that were
embedded. While both types of microcapsules caused FBR (as
expected in such a ﬁbrotic environment), there appeared to be
differences. Unmodiﬁed SLG100 microcapsules had a dense and
thick collagen deposition as indicated by the dark blue color with
Masson’s trichrome staining and also induced a great number of
inﬂammatory cells as indicated by the red color (Fig. 4k and
Supplementary Fig. 31a for two pigs, respectively). On the
contrary, SB-SLG100 microcapsules were observed to have a
looser and thinner collagen deposition and were covered with a
smaller number of inﬂammatory cells, as shown in Fig. 4l and
Supplementary Fig. 31b. Moreover, periodic acid-schiff (PAS)
staining of retrieved tissue showed that unmodiﬁed SLG100
microcapsules (Fig. 4m and Supplementary Fig. 32a) were
generally associated with thicker and more mature bands of
ﬁbrous connective tissue, and had a marked FBR which included
a chronic-active inﬂammatory cell inﬁltrate (lymphocytes and
neutrophils), reactive ﬁbroplasia, and foreign body giant cells
(Fig. 4m, arrow). SB-SLG100 microcapsules (Fig. 4n and
Supplementary Fig. 32b) had thinner and more wispy bands of
connective tissue, and had a relatively reduced FBR including
reduced ﬁbroplasia, fewer chronic inﬂammatory cells (lympho-
cytes) and fewer/smaller multinucleated cells. H&E staining of
cross-sections (Supplementary Fig. 33) conﬁrmed that there was
less cellular inﬁltration among the SB-SLG100 microcapsules
compared with the SLG100 control. While more experiments
with a larger n are required to perform quantitative, statistical
comparisons, qualitatively the SB-alginate was shown to induce
less FBR than the control even in a challenging, pro-ﬁbrotic
environment. All the results from mice, dogs, and pigs combined
together point to the FBR or CO-mitigation effect of zwitterionic
modiﬁcations for alginate microcapsules across species and at
different implantation sites.
Improvement of diabetes treatments in mice. After conﬁrming
that the zwitterionically modiﬁed alginates SB-SLG20 mitigated
FBR in C57BL/6J mice and large animals, we explored its ther-
apeutic potential as a cell encapsulation medium for treatment of
T1D. SB-SLG20 microcapsules (Size: 800~1000 μm; the size dis-
tribution as shown in Supplementary Fig. 34) encapsulating rat
islets (500 islet equivalents per mouse) were transplanted into the
peritoneal cavity of streptozotocin (STZ)-induced C57BL/6J dia-
betic mice and evaluated for 90 days for their ability to restore
normoglycemia. Rat islets were also encapsulated in unmodiﬁed
SLG20 microcapsules as control (Fig. 5a). The BG level of the
mice decreased to normal glycemic range (BG < 200mg/dL) a few
days after transplantation (Fig. 5b) for both groups. However,
mice from the control group (i.e., unmodiﬁed microcapsules)
experienced a shorter duration of glycemic control and four out
of the six mice were unable to sustain normoglycemia within
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90 days, whereas all the mice from the SB-SLG20 group remained
normoglycemic for 3 months before the microcapsules were
retrieved. We also performed an intraperitoneal glucose tolerance
test (IPGTT) (Fig. 5c) 90 days after transplantation, immediately
prior to retrieval on selected mice. While three mice with lowest
BG levels from the SLG20 control group failed to reduce BG to
normoglycemic range even 180 min after glucose challenge, mice
in the SB-SLG20 group (n= 3) achieved normoglycemia within
90 min, conﬁrming the improved function of transplanted islets
(Fig. 5c). Furthermore, the glucose-stimulated insulin secretion
(GSIS) assay performed on the retrieved SB-SLG20 microcapsules
(Fig. 5d) showed that encapsulated islets were responsive to
glucose change and secreted insulin, further supporting for nor-
mal islet function.
Post-retrieval characterizations also showed marked differences
between the SB-SLG20 microcapsules and control microcapsules,
with the former showing almost no cellular deposition (Fig. 5e and
Supplementary Fig. 35). Over 90% of SB-SLG20 microcapsules fell
into the 0–25% PCO category (Supplementary Fig. 36). In the
SB-SLG20 microcapsules, there were numerous rat islets (See
Fig. 5e and Supplementary Fig. 35 for all samples n= 6 from two
batches) observed with healthy morphology (H&E staining in
Fig. 5f) and positive insulin staining (Fig. 5g). On the contrary,











Fig. 4 SB modiﬁed alginates mitigate FBR in dogs and pigs. a A laparoscopic image during retrieval of SB-SLG20 alginate microcapsules, 45 days after
intraperitoneal implantation in a dog. b A laparoscopic image during retrieval of SLG20 control microcapsules. c A phase contrast image of retrieved SB-
SLG20 microcapsules (n= 3; scale bar, 2 mm; see Supplementary Fig. 28 for complete data). d Retrieved SB-SLG20 microcapsules in a Petri dish. e H&E
stained cross-sectional image of retrieved SB-SLG20 microcapsules (Scale bar, 500 μm). f A phase contrast image of retrieved SLG20 microcapsules (n=
1; scale bar, 2 mm). g H&E stained cross-sectional image of retrieved SLG20 microcapsules (Scale bar, 500 μm). h A laparoscopic image during retrieval of
SB-SLG20 alginate microcapsules, 90 days after intraperitoneal implantation in a dog. i A phase contrast image of retrieved SB-SLG20 microcapsules (n=
2; scale bar, 2 mm; see Supplementary Fig. 29 for complete data). j H&E stained cross-sectional image of retrieved SB-SLG20 microcapsules (Scale bar,
500 μm). k Representative Masson’s trichrome staining (and a higher magniﬁcation) images of retrieved SLG100 alginate microcapsules (n= 2; scale bar,
500 μm), 1 month after implantation into the pig omental bursa. l Representative Masson’s trichrome (and a higher magniﬁcation) staining images of
retrieved SB-SLG100 alginate microcapsules (n= 2; scale bar, 500 μm).m PAS-stained histology (and a higher magniﬁcation; scale bar, 200 μm) images of
retrieved SLG100 microcapsules (Scale bar, 1 mm). Arrow indicates foreign body giant cells. n PAS-stained histology (and a higher magniﬁcation; scale bar,
200 μm) images of retrieved SB-SLG100 microcapsules (scale bar, 1 mm)
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(See Fig. 5h, Fig. 5i and Supplementary Fig. 37 for all samples n=
6 from two batches). Approximately 19.1% of all retrieved SLG20
microcapsules were within the 0–25% PCO range and 48.3% fell
into the 75–100% PCO category (Supplementary Fig. 36).
Approximately 75% of the SLG20 microcapsules from the 2
normoglycemic mice had moderate to little CO, while the majority
of the microcapsules from the 4 failed mice had severe cellular
deposition, suggesting a correlation between CO level and diabetes
correction. As expected, the islets in the microcapsules with
cellular deposition either exhibited unhealthy morphology or were
completely dead as shown by the H&E staining of cross-sections
(Fig. 5j).
To further study the robustness of the SB-alginate in improving
islet encapsulation and sustaining normoglycemia, we performed
a longer-term, 200-day transplantation experiment. Four out of
the six diabetic mice transplanted with rat islets encapsulated
in SB-SLG20 microcapsules maintained normoglycemia after
200 days (Fig. 6a); the shortest duration of glycemic control was
~135 days. However, almost all the mice transplanted with rat
islets encapsulated in SLG20 microcapsules returned to
hyperglycemia by 100 days after implantation. An IPGTT assay
(Fig. 6b) 200 days after transplantation, right before retrieval
showed that the mice (cured ones, n= 3) in the SB-SLG20 group
cleared BG and restored normoglycemia at a rate comparable to
that of non-diabetic mice, while the BG of the mice (n= 3) in the
SLG20 control group failed to drop to normal range after 150
min, similar to non-transplanted diabetic mice. For the SB-SLG20
group, an ex vivo GSIS (Fig. 6c) of islets retrieved from cured
mice (n= 3) indicated again the normal function of islets. Dark-
ﬁeld microscopic images of retrieved SB-SLG20 microcapsules
(See Fig. 6d and Supplementary Fig. 38 for all samples n= 6 from
two batches) from normoglycemic mice after 200 days revealed
no or minimal cellular deposition on the microcapsules and the
presence of numerous islets inside. PCO quantiﬁcation showed
that 81.5% of SB-SLG20 microcapsules were largely free of CO
(Supplementary Fig. 39). More importantly, the retrieved islets
were functional, as veriﬁed by H&E histological analysis (Fig. 6e)
and positive insulin staining (Fig. 6f). In contrast, the SLG20
microcapsules produced severe CO as shown by dark-ﬁeld phase






































































Fig. 5 SB-SLG20 microcapsules improve diabetes correction in mice in a 90-day study. a A dark-ﬁeld phase contrast image of SLG20 microcapsules
encapsulating rat islets before transplantation. Scale bar, 1 mm. b Blood glucose concentrations of mice (n= 6 per treatment group). c Intraperitoneal
glucose tolerance test (IPGTT) before retrieval (n= 3). d Ex vivo glucose-stimulated insulin secretion (GSIS) of retrieved islet-containing SB-SLG20
microcapsules, n= 3, Mean ± SEM, *P < 0.05. e A dark-ﬁeld phase contrast image of retrieved islet-containing SB-SLG20 microcapsules (n= 6; see
Supplementary Fig. 35 for complete data. Scale bars, 2 mm on the left and 1 mm on the right). f An H&E stained cross-sectional image of retrieved islet-
containing SB-SLG20 microcapsules. Scale bar, 500 μm. g Immunohistochemical staining of a rat islet in a retrieved SB-SLG20 microcapsule. Insulin is
stained red and nuclei are stained blue (Scale bar, 50 μm). h, i Dark-ﬁeld phase contrast images of retrieved islet-containing SLG20 microcapsules from the
normoglycemic mouse group (h) and failed ones (i). (n= 6; scale bar= 2mm; see Supplementary Fig. 37 for complete data). j An H&E stained cross-
sectional image of retrieved islet-containing SLG20 microcapsule (Scale bar, 200 μm)
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Fig. 40 for all samples n= 6 from two batches), by the PCO
quantiﬁcation (Supplementary Fig. 39), and by the H&E staining
(Fig. 6h). The H&E staining also showed unhealthy or non-viable
morphology of encapsulated islets and the immunohistochemical
staining of insulin (Fig. 6i) was negative. Furthermore, the
retrieval rate for the SB-SLG20 microcapsules was signiﬁcantly
higher than that for the SLG20 microcapsules (Supplementary
Table 2). Taken together, the SB modiﬁcation drastically
improved the outcome of islet microencapsulation, achieving
long-term glycemic correction for up to 200 days in STZ-treated
C57BL/6J mice.
Discussion
FBR against implanted biomaterials and medical devices repre-
sents a major hurdle to many biomedical engineering applications,
particularly cell encapsulation. Unfortunately, despite its impor-
tance, FBR is an incompletely understood process involving
complex biological cascades and high heterogeneity. For alginate
microcapsules, which have been used for decades for cell encap-
sulation, it has been shown that many parameters including types
of alginates39,51, purity of alginate (presence of endotoxins, pro-
teins, and polyphenols)39,52, alginate compositions53–56, micro-
capsule size41,57 and subtle changes in formulations58–62 can all
affect the degree of FBR or CO. Furthermore, the presence or
absence of additional coating layers such as poly-L-lysine or
chitosan resulted in varying degrees of CO63,64. The choice of
cross-linking ions (usually calcium or barium) was reported to
inﬂuence inﬂammatory response against alginate-based cap-
sules65. Alginate capsules containing anti-inﬂammatory drugs has
been employed as a strategy to mitigate the CO and improve the
implantation outcome66,67. However, reproducibility of micro-
capsule performance even in mice has been a challenge for the
ﬁeld. Different labs often report different results in terms of
CO19,41,68–70. Indeed, we have often observed in our laboratory
variations of CO against the unmodiﬁed control microcapsules
between experiments, among different animals in the same
experiment, and even among different microcapsules within the
same animal. In our present study, we made signiﬁcant efforts to
retrieve, image and analyze all microcapsules from all mice. For
unmodiﬁed control microcapsules, while there always existed a
small fraction that were relatively clean, the majority of them had
CO to different degrees. These observations were consistent with
those reported recently for microcapsules made of similar algi-
nates with similar dimensions (<1mm)41. In contrast, for the
zwitterionically modiﬁed alginates, we observed consistent and
uniform reduction (and in some cases elimination) of CO.
Additional large-animal experiments showed that the FBR-
mitigating effect was reproducible across different animal species
including C57BL/6J mice, dogs and pigs.
Although CO-mitigating, chemically modiﬁed alginates have
been reported previously, those “hits” were discovered by time-
consuming screenings of a total of 774 different types of chemical
modiﬁcations23. Our zwitterionic modiﬁcation of alginates
represents a simpler and much less expensive approach and led to
alginate derivatives that were shown comparable to those
obtained by screening. The rationale is based on the well-studied
anti-fouling properties of zwitterionic moieties. In this work, we
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Fig. 6 SB-SLG20 microcapsules improve diabetes correction in mice in a 200-day study. a Blood glucose concentrations of mice (n= 6 mice per treatment
group). b Intraperitoneal glucose tolerance test (IPGTT) before retrieval (n= 3). c Ex vivo GSIS of the retrieved rat islets from SB-SLG20 microcapsules,
n= 3, Mean ± SEM, *P < 0.05. d A dark-ﬁeld phase contrast image of retrieved islet-containing SB-SLG20 microcapsules. (n= 6; scale bar, 2 mm; see
Supplementary Fig. 38 for complete data). e An H&E stained cross-sectional image of retrieved islet-containing SB-SLG20 microcapsules. Scale bar,
500 μm. f Immunohistochemical staining of rat islets in retrieved SB-SLG20 microcapsules. Insulin is stained red and nuclei are stained blue (Scale bar:
50 μm). g A dark-ﬁeld phase contrast image of retrieved islet-containing SLG20 microcapsules. (n= 6; scale bar, 2 mm; see Supplementary Fig. 40 for
complete data). h An H&E stained cross-sectional image of retrieved islet-containing SLG20 microcapsules. Scale bar, 500 μm. i Immunohistochemical
staining of rat islets in retrieved SLG20 microcapsules. Insulin staining is negative and nuclei are stained blue. Scale bar, 500 μm
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effect. Our data, consistent with literature34,71, supported that
zwitterionic groups due to their strong hydration mitigated
nonspeciﬁc protein adsorption which is a key ﬁrst step in foreign
body responses. Likely as a result of the decreased protein
adsorption, the zwitterionic modiﬁcation altered macrophage
activation, TLR2 inhibition and cytokine expression in the peri-
toneal ﬂuid which might be contributing factors to the observed
CO mitigation. Despite these studies, more work is required to
elucidate the exact mechanisms.
To demonstrate and conﬁrm the CO-mitigating effect of
zwitterionic modiﬁcation, we modiﬁed three different ultrapure,
sterile alginates (VLVG, SLG20 and SLG100) and used three
different zwitterions, a SB and two CBs. All the zwitterionically
modiﬁed alginates (SB-alginates, CB1-alginate and CB2-alginate)
were shown to mitigate CO compared to the unmodiﬁed control.
Incorporating a zwitterionic moiety into alginate therefore opens
up a new avenue for the design and development of super-
biocompatible alginates.
The therapeutic potential of the SB modiﬁed alginate was
explored through a type 1 diabetic mouse model using rat islets.
Even in the presence of rat islets (i.e., xenogeneic tissue), the SB-
SLG20 microcapsules had no or minimal CO in C57BL/6J mice,
while the unmodiﬁed, control SLG20 microcapsules were mostly
covered by CO. The reduced CO correlated with an improved
outcome for islet encapsulation and transplantation. The SB-
SLG20 microcapsules encapsulating rat islets enabled longer and
more robust correction of STZ-induced diabetes in C57BL/6J
mice. A 200-day cure was achieved for four out of six mice using
SB-SLG20 microcapsules. Moreover, the ability of zwitterionic
modiﬁcation to mitigate FBR was translatable to higher-order
species (dogs and pigs) and in different implantation sites
(intraperitoneal cavity and omental bursa), suggesting great
potential for future clinical applications. Zwitterionic materials
have been used for a number of applications including fabrication
of antifouling surfaces, grafting of implantable devices and bio-
sensors, and formation of drug delivery micelles and
nanogels26,28,72–77. Here, we report the use of zwitterionically
modiﬁed materials for cell encapsulation for potential T1D
treatment. This approach may contribute to a cell replacement
therapy for not only T1D but also other hormone-deﬁcient dis-
eases such as hemophilia.
Methods
Study design. The aim of this study was to explore whether zwitterionically
modiﬁed alginates could mitigate CO reproducibly at various implantation time
points and across different species. To test this, all experiments using C57BL/6J
mice, Sprague Dawley rats, and Beagle dogs were conducted at Cornell University,
approved by the Cornell Institutional Animal Care and Use Committee, and car-
ried out by trained personnel. Transplantation of alginate microcapsules in insulin
treated type 1 STZ-induced Göttingen minipigs was performed at Novo Nordisk A/
S, and the protocols were approved by the Danish Animal Experimentation
Inspectorate and carried out by trained and licensed personnel. Alginate micro-
capsules were retrieved and imaged, and histopathology using H&E as well as
special stains was performed by trained individuals.
Materials/reagents. Di-tert-butyl dicarbonate, triethylamine, N, N-Dimethy-
lethylenediamine, β-Propiolactone, tert-butyl bromoacetate, barium chloride,
magnesium sulfate, magnesium chloride hexahydrate, phosphate-buffered saline
(PBS; pH 7.4, 10 mM, 138 mM NaCl, 2.7 mM KCl), HEPES buffer, diethyl ether,
ethyl alcohol, acetonitrile and dichloromethane (DCM) were obtained from Sigma-
Aldrich. 2-chloro-4, 6-dimethoxy-1, 3, 5-triazine (CDMT), N-methylmorpholine
(NMM), 1, 3-propanesultone and triﬂuoroacetic acid (TFA) were purchased from
the Alfa Aesar. All the sodium alginates including VLVG (>60% G, 25 kDaMW),
SLG20 (>60% G, 75–220 kDaMW), and SLG100 (>60% G, 200–300 kDaMW),
were purchased from FMC BioPolymer Co. (Philadelphia, PA). Cyano-
functionalized silica was purchased from SiliCycle. Rabbit anti-insulin antibodies
(Cat. #ab63820) was purchased from Abcam, and Alexa Fluor 594-conjuaged
donkey anti-rabbit igG (Cat. #A-21207) was purchased from Invitrogen. α-smooth
muscle actin (SMA) (Cat. #C6198) was purchased from Sigma-Aldrich, and anti-
mouse CD68 (Cat. #137012) was purchased from BioLegend. Anti-mouse F4/80
(Cat. MF48000) was purchased from ThermoFisher, and anti-CD11b (Cat.
#ab133357) was purchased from Abcam. Anti-mouse Ly-6G/Ly-6C (Cat. #108419)
was purchased from BioLegend. Proteome proﬁler array kit (Mouse Cytokine
Array Panel A; Cat. #ARY006) was purchased from R&D Systems.
Synthesis of SB-based conjugates. Synthesis of SB-NH2 material is shown in
Supplementary Fig. 1. Brieﬂy, di-tert-butyl dicarbonate (10.0 g, 45.8 mmol) and
triethylamine (12.8 mL, 91.6 mmol) were added dropwise over 0.5 h to a solution of
N, N-Dimethylethylenediamine (4.04 g, 45.8 mmol) in anhydrous ethyl alcohol
(150 mL) at 0 °C. The mixture was stirred for 1 h at 0 °C and then for 18 h at room
temperature. The white precipitate was ﬁltered off and the ﬁltrate was evaporated
to obtain residue. The residue was dissolved in dichloromethane (150 mL), and the
solution was washed successively with water. The organic layer was dried over
anhydrous magnesium sulfate and evaporated to get N, N-dimethyl-2-((pivaloy-
loxy) amino) ethan-1-amine. 1H NMR (CDCl3, 400 MHz): δ 3.22 (t, 2H), 2.29 (t,
2H), 2.22 (s, 6H), 1.43 (s, 9H).
N, N-dimethyl-2-((pivaloyloxy) amino) ethan-1-amine (7.52 g, 40.0 mmol), 1,
3-propanesultone (4.9 g, 40.0 mmol) and acetonitrile (150 mL) were added into a
300 mL round-bottom ﬂask. The mixture was stirred under nitrogen atmosphere
for 48 h at 40 °C. After reaction, the solvent was removed by rotary evaporator. The
product was precipitated by anhydrous diethyl ether and washed with anhydrous
diethyl ether to get white powder. 1H NMR (D2O, 400MHz): δ 3.41–3.63 (m, 6H),
3.17 (s, 6H), 2.98 (m, 2H), 2.24 (m, 2H), 1.43 (s, 9H).
Finally, 10.0 g of the obtained product was treated with a mixture of 20 mL
triﬂuoroacetic acid (TFA) and 20 mL dichloromethane overnight at room
temperature, concentrated with rotary evaporator, precipitated in anhydrous
diethyl ether, and re-dissolved in DI water. Ion-exchange resin (Amberlyst A26,
OH-form) was added into the solution for complete neutralization. The residue
was lyophilized by freeze dryer to obtain product (SB-NH2 material). 1H NMR
(D2O, 400MHz): δ 3.70 (t, 2H), 3.54 (m, 4H), 3.20 (s, 6H), 2.97 (t, 2H), 2.24
(m, 2H).
Synthesis of SB-modiﬁed alginate: 0.5 g of VLVG alginate, SLG20 alginate or
SLG100 alginate was soluble in 50 mL mixture solvent (40 mL of DI water and
10 mL acetonitrile). 225 mg of 2-chloro-4, 6-dimethoxy-1, 3, 5-triazine (CDMT)
and 280 μL of N-methylmorpholine (NMM) were added. Then 0.36 g of SB-NH2
material was dissolved in 10 mL DI water and added into the mixture. The reaction
was stirred overnight at 60 °C. The solvent was removed under reduced pressure
and the solid product was redissolved in DI water. The solution was ﬁltered
through a pad of cyano-functionalized silica. It was then dialyzed against a 10,000
MWCO membrane in DI water for three days. Finally, the water was removed by
freeze dryer to obtain SB-modiﬁed alginate. 1H NMR (D2O, 400MHz): δ 3.5–5.3
(m, alginate protons), 3.87 (m, 2H), 3.61 (m, 4H), 3.14 (s, 6H), 2.91 (t, 2H), 2.20
(m, 2H). There was about 30.5% modiﬁcation degree of the starting alginate
through NMR analysis.
Synthesis of CB-based conjugates. Synthesis of CB1-NH2 materials is shown in
Supplementary Fig. 8. Brieﬂy, N, N-dimethyl-2-((pivaloyloxy)amino)ethan-1-
amine (7.52 g, 40.0 mmol), tert-butyl bromoacetate (7.8 g, 40.0 mmol) and acet-
onitrile (150 mL) were added into a 250 mL round-bottom ﬂask. The mixture was
stirred under nitrogen atmosphere for 48 h at 40 °C. After reaction, the solvent was
removed by rotary evaporator. The product was precipitated by anhydrous diethyl
ether and washed with anhydrous diethyl ether three times to get white powder. 1H
NMR (D2O, 400MHz): δ 4.21 (s, 2H), 3.72 (m, 2H), 3.57 (m, 2H), 3.31 (s, 6H),
1.32–1.54 (s, 18H).
Finally, 5.0 g of the obtained product was treated with a mixture of 20 mL
triﬂuoroacetic acid and 20 mL dichloromethane overnight at room temperature,
concentrated with rotary evaporator, precipitated in anhydrous diethyl ether, and
redissolved in DI water. Ion-exchange resin (Amberlyst A26, OH-form) was added
into the solution for complete neutralization. The residue was lyophilized by freeze
dryer to obtain product (CB1-NH2 monomer). 1H NMR (D2O, 400MHz): δ 4.31
(s, 2H), 3.99 (t, 2H), 3.55 (t, 2H), 3.36 (s, 6H). The CB2-NH2 monomer as shown in
Supplementary Fig. 9 was synthesized using the same procedure as that for CB-1-
NH2 monomer. 1H NMR of CB2-NH2 (D2O, 400MHz): δ 3.63–3.75 (m, 4H), 3.53
(m, 2H), 3.18 (s, 6H), 2.96 (t, 2H).
Synthesis of CB-modiﬁed alginates: The CB1-alginate and CB2-algiante
conjugates were synthesized using the same procedure as that for SB-alginate
conjugate. The chemical structures of these CB-based alginate conjugates were
conﬁrmed by NMR. 1H NMR of CB1-alginate: δ= 3.5–5.3 (m, alginate protons),
3.84–4.10 (m, 4H), 3.72 (m, 2H), 3.34 (s, 6H). There was about 33.1% modiﬁcation
degree of the starting alginate through the NMR analysis. 1H NMR of CB2-
alginate: δ= 3.5–5.3 (m, alginate protons), 3.87–4.06 (m, 4H), 3.80 (m, 2H), 3.39 (s,
6H), 2.95 (m, 2H). There was about 24.7% modiﬁcation degree of the starting
alginate through NMR analysis.
Preparation of SB-based or CB-based alginate microcapsules. All the buffers
were sterilized, and alginate solutions were ﬁltered using a 0.2 μm ﬁlter before use.
2% (w/v) alginate (VLVG, SLG20, or SLG100) was dissolved in saline solution to
prepare an alginate solution. 2% (w/v) SB-based alginate conjugate was dissolved in
saline solution. The mixture of 60% (by volume) SB-based alginate solution and
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40% (by volume) SLG100 solution were blended to obtain the SB-alginate solution.
The CB-alginate solution was prepared using the same procedure.
Alginate hydrogel microcapsules were made using a custom-built
electrospraying setup. Brieﬂy, a high voltage power generator was connected to a
blunt-tipped needle. This needle was attached to a 3 mL syringe containing alginate
solution clipped to a vertically oriented syringe pump. Various sizes of
microcapsules were prepared using different voltage, ﬂow rate and needle gauges;
500–700 µm microcapsules were prepared using a voltage of 8–9 kV, a 0.2 mL/min
ﬂow rate and a 25-gauge blunt needle (SAI Infusion Technologies), 800–1000 µm
microcapsules were prepared using a voltage of 6–7 kV, a 0.2 mL/min ﬂow rate and
a 20-gauge blunt needle (SAI Infusion Technologies). Alginate solution was
sprayed into a sterile, grounded dish containing a 20 mM barium chloride solution.
Once the alginate microcapsules were fabricated, they were collected immediately
and washed with prepared HEPES buffer [NaCl 15.43 g, KCl 0.70 g, MgCl2•6H2O
0.49 g, 50 mL of HEPES (1 M) buffer solution in 2 L of DI water] three times and
then washed additional two times with saline and kept at 4 °C before use.
Protein adsorption. Two percent of SB modiﬁed alginate solution and two percent
of SLG100 alginate solution were mixed at a 60:40 (v/v) ratio. Two percent of
SLG20 was used as control. 0.2 mL of the above alginate solutions were added to a
24-well plate. Then, 0.2 mL of barium chloride solution (20 mM) as a cross-linking
buffer was slowly added on the top of the gel. After 1 h solidiﬁcation, these alginate
hydrogels were removed from plates and washed with PBS ﬁve times before use.
The above alginate hydrogels were immersed in FITC-labeled ﬁbrinogen
solution (0.1 mg/mL in PBS) or FITC-labeled lysozyme solution (0.1 mg/mL in
PBS) at room temperature for 1 h to allow protein adsorption on the hydrogel
surfaces. Hydrogels were then gently washed with PBS ﬁve times to remove the
unbound protein molecules. Fluorescence images of hydrogel surfaces were taken
using a ﬂuorescence microscope with 10× lens at a ﬁxed exposure time. To ensure
that all hydrogel samples were focused on the same plane, all images were taken at
the edge of the hydrogels. The ﬂuorescent intensity was quantiﬁed and analyzed
using ImageJ software.
Mechanical strength of microcapsules. The mechanical properties of different
alginate microcapsules was tested with a Texture Analyzer XT plus (Stable Micro
Systems, Godalming, UK) equipped with a force transducer (Resolution: 1 mN).
Microcapsules were carefully monitored under a dissection microscope (Bausch
and Lomb BVB-125). Uniaxial compression tests were performed as follows: a
mobile probe (P/25L) with pretest speed of 0.5 mm/s, a test speed of 0.01 mm/s,
and a post-test speed of 2 mm/s was used to compress individual microcapsules
(n= 10) with a trigger force of two grams. The force (grams) was quantiﬁed at a
60% compression of the sample. Resulting measurements were analyzed via Tex-
ture Exponent software (v6.0).
Mass transfer studies. To measure the diffusion rate of the unmodiﬁed and
modiﬁed alginate hydrogels, we immersed SLG20 and SB-SLG20 hydrogels into
three different saline solutions containing 10, 70, and 250 kDa FITC-labeled dex-
trans (1 mg/mL), respectively. The ﬂuorescent intensity of the alginate hydrogel
was analyzed using confocal microscopy.
Surface roughness of capsules. Single capsules were carefully selected using a
dissection microscope (Leica MZ75 microsystems), washed and placed on micro-
scopic slides. The surface roughness of different microcapsules was determined by
a Bruker Catalist atomic force microscope (AFM) with a Bruker DNP silicon
nitride cantilever. Topographic imaging of the capsules was performed at room
temperature using the contact mode. Surface roughness was calculated by using the
NanoScope Analysis 1.8 software.
Zeta potential measurement. Unmodiﬁed and modiﬁed alginate nanogels were
prepared via a surfactant-free and organic solvent-free method78. Brieﬂy, sodium
alginate was mixed with ionic calcium by in situ crosslinking under ultrasound, and
alginate nanogels were obtained. Zeta potentials of alginate nanogels were then
investigated using Zetasizer Nano ZS (Malvern, U.K.). The value was recorded as
the mean of ﬁve measurements.
TLR signaling. To study whether zwitterionic modiﬁed alginate alters TLR sig-
naling, we performed the HEK-BlueTM TLR cell-based assays (InvivoGen, France)
according to the manufacturer’s protocol. These HEK-BlueTM cells express the
Soluble Embryonic Alkaline Phosphatase (SEAP) gene which can be quantiﬁed
using Quantiblue (InvivoGen, France)39,79. The SEAP gene is under the control of
the NFκB/AP-1 responsive promoter. The information of cell lines, antibiotics, and
concentration of agonists used to activate TLR signaling were shown in Supple-
mentary Table 3. All cell lines were cultured in DMEM culture media (Lonza,
Basel, Switzerland) supplemented with 10% de-complemented Fetal Calf serum, 50
U/ml Penicillin (Sigma, St. Louis, MO, USA), 50 μg/ml Streptomycin (Sigma, St.
Louis, MO, USA) and 100 μg/ml Normocin (InvivoGen, Toulouse, France). HEK-
BlueTM cell lines for TLR2 expressing cells at a density of 2.8 × 105 cells/ml and
HEK- BlueTM cell lines for TLR4 expressing cells at a density of 1.4 × 105 cells/ml,
were seeded in 96-well plates at 180 µl/well, respectively. After overnight culture,
Cells were treated with 25 alginate capsules or TLR agonists as control to study
whether alginate capsules can activate TLR signaling (Supplementary Table 3).
Inhibition of TLR was studied by exposing HEK-BlueTM cells with 25 alginate
capsules for 1 h, followed by treatment with TLR agonists (Supplementary Table 3).
QUANTI-Blue™ medium (InvivoGen, Toulouse, France) change to a purple-blue
color in the presence of SEAP. Media supernatant from the stimulated cell-lines
was mixed with QUANTI-Blue™ medium in a ratio of 1:10 (v/v). Activation of
NFκB was ﬁnally quantiﬁed at 655 nm using a Versa Max ELISA plate reader
(Molecular devices, Sunnyvale, CA, USA). The assay was performed with six
repeats.
Cytokine secretion. All animal procedures were approved by the Institutional
Animal Care and Use Committee at the University of California Irvine prior to
initiation of the study. BMDM were harvested from the femurs or tibia of 6–8
week-old C57BL/6J mice (Jackson Laboratories). Cells were treated with ACK lysis
buffer (Invitrogen), centrifuged, and resuspended in D-10 media. D-10 media
consists of Dulbecco’s modiﬁed Eagle medium (DMEM), 10% heat-inactivated
FBS, 2 mM L-glutamine, 100 units per mL penicillin–streptomycin, and 10%
conditioned media from CMG 14–12 cells expressing macrophage colony stimu-
lating factor (M-CSF)80. After culture for one week, BMDM were dissociated using
cell dissociation buffer (Invitrogen), and seeded on the tissue culture plates at a cell
density of 100,000 cells/cm2 (Olympus Plastics) in fresh D-10 culture media. At 6 h
culture after cell seeding, 10% of 500 μm various alginate capsules (v/v) were added
and stimulated with a combination of 0.3 ng/mL lipopolysaccharide (LPS) and
1.0 ng/mL inter-feron gamma (IFNγ). After 12 h of incubation, the supernatants
were collected and analyzed for TNF-α secretion by enzyme-linked immunosor-
bent assay (ELISA) following the manufacturer’s instructions (BioLegend).
Rat islet isolation, puriﬁcation, and encapsulation. Male Sprague-Dawley rats
from Charles River Laboratories weighing about 300 g were used for harvesting
islets. All rats were anesthetized using 3% isoﬂurane in oxygen throughout the
whole procedure. Isolation surgeries were performed following by Lacy and Kos-
tianovsky81. Brieﬂy, the port vein was clamped and rat bile duct was cannulated.
The pancreas was distended by an in vivo injection of cold 0.15% Liberase
(Research Grade, Roche) in RPMI 1640 media solution. The perfused pancreatic
organs were removed and put into 50 mL conical tubes on ice until the end of all
surgeries. All the tubes containing the pancreas were then placed into in a 37 °C
water bath for a 29 min digestion. After that, the digestion was quenched by adding
cold M199 media containing 10% heat-inactivated fetal bovine serum (HIFBS) and
lightly shaking. Digested pancreases were washed twice by the same aforemen-
tioned M199 media, ﬁltered through a 450 mm sieve, and then suspended in a
Histopaque 1077 (Sigma)/M199 media gradient and centrifuged at 1700 RCF at
4 °C. This gradient centrifugation step was repeated for higher purity islets. Finally,
these islets were further isolated by a series of six gravity sedimentations, in which
each supernatant was discarded after 4 min of settling. Puriﬁed islets were hand-
picked under the microscope and washed by sterile saline solution. Islets were then
cultured overnight in RPMI 1640 media with 10% HIFBS and 1% penicillin/
streptomycin for further use.
Prior to islet encapsulation, the cultured islets were centrifuged at 562 RCF for
1 min and washed with saline solution. After washing, islets were centrifuged again
and all supernatant was removed. The islet pellet was then resuspended in a 2%
alginate solution at an islet density of 500 islets. 800–1000 μm alginate
microcapsules containing islets were crosslinked using a BaCl2 gelling solution and
their sizes of microcapsules were controlled using similar procedures as the empty
spheres (described above). After crosslinking, microcapsules with encapsulated
islets were immediately washed ﬁve times with saline solution to remove residual
BaCl2 gelling solution, transferred into corresponding cell culture medium, and
cultured 4 h at 37 °C prior to implantation. Since the rat islets had variable sizes
(50–300 µm) and also there was an inevitable loss of islets during the process of
encapsulation, the total number of encapsulated islets was converted into islet
equivalents (IE, normalized to 150 µm size) following a previously published
method82.
Implantation and retrieval in mice. Immuno-competent male C57BL/6J mice
were used for transplantation. To create insulin-dependent diabetic mice, healthy
C57BL/6J mice were treated (50 mg/kg mouse) with freshly prepared streptozocin
(STZ) (Sigma Aldrich) solution (7.5 mg/mL in sodium citrate buffer solution) for 5
consecutive days. The BG levels of all the mice were monitored before trans-
plantation. The mice whose non-fasted BG levels of the mice were above 300 mg/
dL, were considered to be diabetic. All the mice were anesthetized using 3% iso-
ﬂurane in oxygen and maintained at the same rate throughout the procedure. Prior
to transplantation, all mice were injected a 0.05 mg/kg dose of buprenorphine
subcutaneously as a pre-surgical analgesic, and their abdomens were shaved and
sterilized using betadine and isopropyl alcohol. A 0.5 mm incision was made along
the midline of the abdomen and the peritoneal lining was exposed using blunt
dissection. The peritoneal wall was then grasped with forceps, and a 1-mm incision
was made along the linea alba. A desired volume of empty microcapsules or
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islets-containing microcapsules loaded into a sterile pipette were implanted into the
peritoneal cavity through the incision. The incision was closed using 5–0 taper
tipped polydioxanone (PDS II) absorbable sutures. The skin was then closed over
the incision using a wound clip.
The empty microcapsules (or with encapsulated rat islets) were retrieved from
mice at desired time points post-implantation. Mice were euthanized by CO2
administration followed by cervical dislocation, and larger (∼3 mm) incisions were
made in the skin and the peritoneum. 100 mM CaCl2 solution was injected into the
abdominal cavity repeatedly and washed out all material microcapsules from the
abdomen. In certain instances, the microcapsules needed to be retrieved manually
if ﬁbrosed directly to intraperitoneal tissues. The retrieved microcapsules were then
submerged into a cross-linking solution containing 100 mM CaCl2 for ∼1 min (It is
noted that the size of capsules became slightly smaller after retrieval especially for
long-term studies possibly due to change of environment from body ﬂuid to a
Ca2+-containing stabilizing buffer that was used to collect the microcapsules), and
transferred into 4% paraformaldehyde for ﬁxation or cell culture medium. Lastly,
the microcapsules were collected and stacked together into Histogel for histological
sectioning.
Implantation and retrieval in dogs. Dogs (Beagle dogs from Marshall Bior-
esources, Clyde, NY) were premedicated with gylcopyrolate and butorphanol,
induced with propofol, and anesthetized using isoﬂurane and oxygen throughout
the surgery. The abdomen was shaved and prepared for sterile surgery. A 10-mm
laparoscopic camera port and two 5-mm instrument ports were percutaneously
inserted into the abdomen. The abdomen was insufﬂated to 12 mm Hg pressure
with CO2. Prior to transplantation, about 10 mL of prepared microcapsules (size:
500 μm) and 30 mL saline solution were loaded into the 60 mL sterilized syringe.
This syringe was then connected with one side of 16-gauge sterile catheter. This
ﬂexible catheter was inserted into the left-side instrument port and used to dis-
tribute the capsules throughout the abdominal cavity. The alginate capsule solution
was gently infused at a rate no greater than 30 mL/min. A laparoscopic probe was
inserted through the right-sided 5-mm port. After implantation, the abdomen was
then desufﬂated and the remaining parts were removed. The port sites were closed
with 3–0 polydioxinone suture material and tissue glue.
The retrieval procedure of microcapsules was conducted using the similar
method described for implantation. The implanted capsules were ﬁrstly located and
photographed. About 100 mL of sterile pre-warmed saline solution was injected to
gently wash the peritoneal cavity and then gently aspirated back into the syringe.
Closure was conducted with the same method described for implantation.
Implantation and retrieval in pigs. Four female Göttingen minipigs (Ellegaard
Minipigs, Dalmose, Denmark) were acclimatized for three weeks. Following
acclimatization, the animals were given 60 mg/kg streptozotocin on three con-
secutive days to induce a type 1 diabetic phenotype. The animals were subsequently
titrated in on long acting exogenous insulin using QD dosing to achieve a target a
plasma glucose ~10–15 mM. The animals were anaesthetized and underwent a
surgical laparotomy performed lege artis. Brieﬂy, the animals were placed in the
dorsal recumbency and the surgical area prepared aseptically, a 6 cm incision was
made from processus xiphoideus and extended the in the caudal direction. The
stomach was identiﬁed and the greater omentum (bursa omentalis) was advanced
to the incision site. The visceral and parietal sheet of the omentum was separate
and a 3 cm incision was made in the parietal sheet. Approximately 30, 000
microcapsules (capsule size: 500–700 μm) suspended in 50 mL of sterile saline
solution were administered into the omentum. The surgical incision was closed lege
artis and the pigs were provided with antibiotic prophylaxis. After 1-month
implantation, the pigs were euthanized with a lethal overdose of euthanal, a full
necropsy was performed and omentum with embeded microcapsules extracted for
histopathology.
Imaging of the retrieved alginate microcapsules. For phase contrast imaging,
retrieved alginate microcapsules were gently washed using saline solution and
transferred into Petri dishes for phase contrast microscopy using an EVOS
AMF4300 imaging system.
Blood glucose monitoring. Starting post-transplantation, a small drop of blood
was collected from the tail vein of each mouse using a lancet and tested using a
commercial glucometer (Clarity One, Clarity Diagnostic Test Group), approxi-
mately three times a week. Mice with unfasted glucose levels below 200 mg/dL were
considered normoglycemic.
IPGTT assay. Prior to retrieval, glucose tolerance tests were performed to assess
metabolic capacity. Mice were fasted overnight before an i.p. injection of glucose
solution (2 g of glucose per 1 kg of body mass). BG levels were monitored at
predetermined time points (0, 15, 30, 60, 90, 120, and 180 min) after injection.
In vitro GSIS assay. Krebs Ringer Bicarbonate (KRB) buffer [98.5 mM NaCl,
4.9 mM KCl, 2.6 mM CaCl2, 1.2 mM MgSO4·7H2O, 1.2 mM KH2PO4 and 25.9 mM
NaHCO3 (all from Sigma-Aldrich) supplemented with 20 mM HEPES and 0.1%%
BSA (Serological)] was prepared beforehand. Encapsulated islets were then incu-
bated for 60 min with 2.8 mM or 16.7 mM d-glucose under the same condition.
The supernatants were collected, and insulin content was quantiﬁed using ultra-
sensitive mouse/rat insulin ELISA kit (ALPCO) with measurement by Synergy 4
Fluorescence Absorbance Microplate Reader (BioTek) at 450 nm wavelengths. All
of the ELISA results were normalized to the IEQs.
Cytokine proﬁling analysis. Semi-quantitative analysis of cytokine/chemokine
levels was performed using Proteome ProﬁlerTMArray, Mouse Cytokine Array
Panel A (ARY006; R&D Systems) according to manufacturer’s instructions. Brieﬂy,
500 μl of intraperitoneal liquid was extracted directly after injection of 1 ml PBS
with proteinase inhibitor. For each membrane, 500 μl of protein solution was
mixed with 500 μl of sample buffer (array buffer 4) and 500 μl of block buffer (array
buffer 6). Fifteen mocroliters of reconstituted Mouse Cytokine Array Panel A
Detection Antibody Cocktail was then added and incubated at room temperature
for 1 h. The array membrane was incubated with block buffer (array buffer 6) for
1 h on a rocking platform shaker. The tray should be oriented to ensure that each
membrane rocks end to end in its well. The block buffer was then aspirated, and
the prepared sample/antibody mixture was added onto the membrane and incu-
bated overnight at room temperature on a rocking platform shaker. Each mem-
brane was washed three times with 20 ml of 1X wash buffer for 10 min on a rocking
platform shaker. Membranes were incubated in 1.5 ml of streptavidin-HRP
(1:1,000 dilution) in array buffer 5 for 30 min at room temperature on a rocking
platform shaker, and then washed with wash buffer three more times. Antibody-
antigen complexes were visualized and analyzed using LI-COR C-Digit.
Histological analysis and immunostaining. The retrieval microcapsules were
ﬁxed in 4% paraformaldehyde, stacked together into Histogel, embedded in par-
afﬁn and then sectioned by Cornell Histology Core Facility. The samples were
sliced on a microtome at a thickness of 5 μm. Parafﬁn sections were then stained
with hematoxylin/eosin.
To conduct immunoﬂuorescence staining of retrieved islets, the histological
slides were deparafﬁnized by sequential washing in xylene, 100, 90, and 75%
ethanol, and DI water. These slides were then boiled in 1 mM EDTA for antigen
exposure. Non-speciﬁc binding was blocked with 10% goat serum for 45 min at
room temperature. After blocking, slides were decanted and incubated with
primary rabbit anti-insulin antibodies (1:200) overnight at 4 °C. The sections were
then washed and incubated with the FITC-conjugated secondary antibodies, 594-
conjuaged donkey anti-rabbit igG (1:400 dilution) for 30 min at room temperature.
Slides were washed twice with water, labeled with DAPI, and covered with
coverslips. Fluorescence images were captured using an EVOS AMF4300 imaging
system.
To conduct immunoﬂuorescence staining of retrieved alginate microcapsules,
samples were ﬁxed in 4% paraformaldehyde overnight before use. Samples were
washed with Krebs Buffer three times. Samples were then washed with PBS three
times and a 1% Triton X-100 solution was used to permeabilize cells. Samples were
incubated for 15 min at room temperature. Samples were then transferred into 1%
albumin solution for 30 min at room temperature. Next, the microcapsules were
incubated for 1 h in an immunostaining cocktail solution consisting two drops of
DAPI and speciﬁc antibodies (1:200) in 1% albumin solution. Staining solution was
then removed and washed twice with PBS solution containing 0.1% tween 20.
Samples were washed twice with PBS and then transferred into a concave glass
slide. Excess PBS was removed, and 50% glycerol solution was added. The samples
were ﬁnally covered with coverslips. Fluorescence Images were captured under a
Zeiss LSM710 confocal microscope at Cornell Biotechnology Resource Center
Imaging Facility.
Evaluation of PCO. The retrieved microcapsules were evaluated using phase-
contrast microscopy to determine the degree of CO following the previous
method43. For retrieved microcapsules, the degree of CO was determined by
categorizing coverage percentage of surface area that was covered by PCO: 0–25,
25–50, 50–75, 75–100%. The PCO degree for retrieved capsules was calculated
using the equation: PCO degree (%)= (the number of capsules assessed in each
category/the total number of retrieved capsules) × 100.
Statistical analysis. Data are expressed as Mean ± SEM in these experiments.
Paired Student’s t-test was used to compare two small sets of quantitative data from
surface roughness, mechanical property, TLRs studies, protein adsorption, mac-
rophage activation studies, and ex vivo GSIS experiments, with P < 0.05 being
considered as statistically signiﬁcant. For PCO quantiﬁcation, Chi-squared test
with Bonferroni correction was used to compare modiﬁed alginates to SLG20
alginate and calculate P values. Differences between groups were considered sta-
tistically signiﬁcant when P < 0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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